Mubadala Investment Co. Acquires UCB Pharma’s Business in China
In a strategic move, UAE sovereign wealth fund Mubadala Investment Co. has secured full ownership of UCB Pharma’s mature business in China, teaming up with CBC Group, a healthcare-focused asset manager.
Expanding Presence in China’s Healthcare Sector
Belgium-based UCB, a prominent global biopharma firm, has established a solid foothold in China’s expanding immunology and neurology markets.
Deal Details and Future Prospects
Though the exact stake size and transaction value were not disclosed, the deal is set to finalize in the fourth quarter of 2024. This acquisition signifies Mubadala’s ongoing effort to strengthen its presence in the Asian market, particularly in the fast-growing healthcare sector.
Strategic Vision and Partnership
Mohamed Al-Badr, head of China at Mubadala, expressed excitement about the partnership with CBC Group to support UCB’s growth in China. He emphasized the company’s commitment to clinical excellence and innovation to enhance access to transformative medicines.
Key Assets and Market Impact
The acquisition covers UCB’s neurology portfolio, including essential drugs like Keppra, Vimpat, and Neupro, vital for treating epilepsy and other neurological disorders in high demand in China. Additionally, the deal includes UCB’s allergy portfolio, featuring Zyrtec and Xyzal.
Forward-Thinking Investment Strategy
Mubadala and CBC Group have also gained ownership of UCB’s Zhuhai manufacturing facility, a crucial site supporting the production and distribution of these medications across mainland China. This move aligns with Mubadala’s vision to expand its presence in Asia through strategic investments in high-growth sectors, with healthcare at the forefront.
Commitment to Patient Care and Innovation
Jean-Christophe Tellier, CEO of UCB, highlighted the company’s dedication to addressing unmet patient needs in China. With plans to introduce novel medicines in immunology, neurology, and rare diseases, UCB aims to drive positive patient outcomes by collaborating with local partners and fostering innovation.